Article: Requip(R) (ropinirole HCl) Tablets Significantly Improve Symptoms of Restless Legs Syndrome (RLS) In Patients With RLS.

Largest U.S. Study in Moderate-to-Severe Primary RLS Published in Mayo Clinic Proceedings

RESEARCH TRIANGLE PARK, N.C., Jan. 3 /PRNewswire/ -- Data published in the January issue of Mayo Clinic Proceedings show that Requip(R) (ropinirole HCl) Tablets significantly improve RLS symptoms. The study, entitled TREAT RLS US (Therapy with Ropinirole, Efficacy and Tolerability in Restless Legs Syndrome), is the largest U.S. study to date of the treatment of Restless Legs Syndrome (RLS). The TREAT RLS US results support previous studies with Requip, the first and only FDA-approved treatment for moderate-to-severe primary RLS.

RLS is a chronic and disruptive ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!